Subsequent Events (Details) - Subsequent [Member] - USD ($)		1 Months Ended
	Jan. 08, 2021	Feb. 23, 2021
Subsequent Events (Details) [Line Items]
Sponsor advanced (in Dollars)		$ 50,000
Merger consideration payable, description	The aggregate merger consideration payable to stockholders of Celularity upon the Closing consists of up to 147,327,224 newly issued shares of Class A common stock of the Company, par value $0.0001 per share (“GX Class A Common Stock”) valued at approximately $10.15 per share.
Preferred stock per share	$ 0.0001
Common Stock convertible, conversion price	$ 0.0001
Subscription agreements, description	On January 8, 2021, concurrently with the execution of the Merger Agreement, the Company entered into separate subscription agreements (the “Subscription Agreements”) with investors (each, a “PIPE Investor”), pursuant to which the PIPE Investors agreed to purchase, and we agreed to sell to the PIPE Investors, an aggregate of 8,340,000 shares of the Company’s Class A Common Stock (the “PIPE Shares”), for a purchase price of $10.00 per share and an aggregate purchase price of $83,400,000, in a private placement (the “PIPE Financing”), a portion of which is expected to be funded by (i) existing Celularity investors and affiliates (the “Celularity-Related PIPE Investors”) and (ii) certain additional investors.
Purchase price per share	$ 10.00